Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.
Phase of Trial: Phase IV
Latest Information Update: 25 May 2018
Price : $35 *
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Tenofovir alafenamide (Primary)
- Indications Hepatitis C; HIV infections
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 10 Jan 2018 Status changed from not yet recruiting to recruiting.
- 01 Dec 2017 Planned End Date changed from 31 Dec 2018 to 31 Aug 2019.